Reminder for Erasca Shareholder Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 45 minutes ago
0mins
Source: PRnewswire
- Class Action Notification: Rosen Law Firm reminds investors who purchased Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Erasca class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected parties to participate in the litigation.
- Legal Violations Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate ERAS-0015 throughout the class period, resulting in investor losses when the truth emerged.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in the field, thereby enhancing investor confidence in its representation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 18.320
Low
2.00
Averages
5.50
High
11.00
Current: 18.320
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for Erasca Shareholder Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Erasca class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected parties to participate in the litigation.
- Legal Violations Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate ERAS-0015 throughout the class period, resulting in investor losses when the truth emerged.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in the field, thereby enhancing investor confidence in its representation.
See More
Multiple Companies Face Class Action Lawsuits
- Erasca Lawsuit Overview: Erasca, Inc. (NASDAQ:ERAS) faces a class action lawsuit for the period from January 14, 2025, to April 26, 2026, alleging that the company failed to disclose improper comparisons in its ERAS-0015 preclinical data, misleading investors about its prospects, with a lead plaintiff motion deadline of August 10, 2026.
- Nano-X Operational Issues: Nano-X Imaging Ltd. (NASDAQ:NNOX) is under scrutiny in a class action lawsuit covering March 31, 2025, to April 17, 2026, for overstating operational efficiency and product demand, while actually facing increased operating expenses and cash burn, requiring lead plaintiff motions by August 11, 2026.
- Microsoft Product Deficiencies: Microsoft Corporation (NASDAQ:MSFT) is implicated in a class action lawsuit for the period from May 1, 2025, to January 28, 2026, alleging significant issues with its Copilot product line, including poor brand positioning and user experience, leading to a decline in market share, with a lead plaintiff motion deadline of August 11, 2026.
- Black Rock Coffee Expansion Risks: Black Rock Coffee Bar, Inc. (NASDAQ:BRCB) faces a class action lawsuit for the period from September 12, 2025, to May 12, 2026, claiming that new store openings cannibalized existing services and revenue, with a lead plaintiff motion deadline of August 17, 2026.
See More
Reminder of Class Action Lawsuits for Shareholders of Multiple Companies
- BitGo Shareholder Lawsuit: BitGo Holdings, Inc. (NYSE:BTGO) faces a class action lawsuit for the period from January 22 to May 13, 2026, alleging that the company failed to disclose the impact of declining digital asset prices on its financial performance, which may undermine investor confidence and affect stock prices.
- Erasca Shareholder Class Action: Erasca, Inc. (NASDAQ:ERAS) is involved in a lawsuit for the period from January 14, 2025, to April 26, 2026, claiming that the company made improper comparisons in its ERAS-0015 preclinical data, failing to disclose potential patent and trade secret risks, which could lead to diminished investor confidence in the company's future.
- Nano-X Shareholder Lawsuit: Nano-X Imaging Ltd. (NASDAQ:NNOX) is facing a class action lawsuit for the period from March 31, 2025, to April 17, 2026, alleging that the company overstated operational efficiencies and product demand, failing to disclose misalignments between production and demand, potentially leading to increased operational costs and cash flow risks for shareholders.
- Microsoft Shareholder Class Action: Microsoft Corporation (NASDAQ:MSFT) is involved in a lawsuit for the period from May 1, 2025, to January 28, 2026, alleging that the company failed to disclose multiple issues facing its Copilot product line, including inadequate brand positioning and user experience, which may impact its market share and future revenue expectations.
See More
Erasca Faces Class Action Lawsuit Risks
- Stock Price Plunge: Erasca's shares plummeted by approximately 53.9%, resulting in an $11.59 loss per share after the revelation of improper preclinical data, indicating a significant crisis in market trust for the company.
- Class Action Initiation: Levi & Korsinsky has filed a class action lawsuit against Erasca, alleging materially false and misleading statements made between January 14, 2025, and April 26, 2026, granting investors the right to seek recovery for their losses.
- Financing Motivation Scrutiny: The lawsuit contends that the $258.8 million common stock offering completed on January 23, 2026, was aimed at maintaining an artificially inflated stock price, raising further concerns about the transparency of the company's management.
- Legal Risks Emerge: Allegations of improper comparisons in preclinical data expose Erasca to potential patent infringement and trade secret misappropriation claims, leaving investors uncertain about the company's future prospects.
See More
Erasca Faces Securities Fraud Class Action Lawsuit
- Class Action Reminder: Bernstein Liebhard LLP reminds investors of Erasca, Inc. (NASDAQ: ERAS) about the August 10, 2026 deadline for a securities fraud class action lawsuit, urging investors to submit forms promptly to participate in the litigation.
- Lawsuit Background: The lawsuit represents investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, alleging violations of the Securities Exchange Act of 1934 by the company and certain senior officers for making materially false and misleading statements regarding business operations, growth prospects, and financial stability.
- Investor Losses: Due to these alleged misrepresentations, Erasca's common stock traded at artificially inflated prices during the class period, leading to significant losses for investors when the truth was revealed, highlighting the legal risks and potential financial implications facing the company.
- Law Firm's Strength: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, demonstrating its expertise and influence in protecting investor rights.
See More
Investors Alert: Class Action Lawsuits Against BitGo and Others
- BitGo Lawsuit Reminder: A class action lawsuit against BitGo Holdings, Inc. alleges that the company failed to disclose the severe risks posed by falling digital asset prices to its financial performance, urging investors who purchased shares and suffered losses to apply for lead plaintiff status by August 7, 2026.
- ADMA Legal Issues: ADMA Biologics, Inc. faces a class action lawsuit claiming misleading statements made between August 9, 2024, and March 25, 2026, with investors needing to apply for lead plaintiff status by August 10, 2026, to protect their rights.
- Erasca Class Action: The class action lawsuit against Erasca, Inc. alleges failure to disclose material facts regarding ERAS-0015 between January 14, 2025, and April 26, 2026, with affected investors required to apply for lead plaintiff status by August 10, 2026.
- Legal Firm Overview: Holzer & Holzer, LLC, a top-rated securities litigation law firm, has been dedicated to vigorously representing shareholders since 2000, recovering hundreds of millions of dollars for victims of corporate misconduct.
See More
Reminder for Erasca Shareholder Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Erasca class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected parties to participate in the litigation.
- Legal Violations Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate ERAS-0015 throughout the class period, resulting in investor losses when the truth emerged.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in the field, thereby enhancing investor confidence in its representation.
See More
Multiple Companies Face Class Action Lawsuits
- Erasca Lawsuit Overview: Erasca, Inc. (NASDAQ:ERAS) faces a class action lawsuit for the period from January 14, 2025, to April 26, 2026, alleging that the company failed to disclose improper comparisons in its ERAS-0015 preclinical data, misleading investors about its prospects, with a lead plaintiff motion deadline of August 10, 2026.
- Nano-X Operational Issues: Nano-X Imaging Ltd. (NASDAQ:NNOX) is under scrutiny in a class action lawsuit covering March 31, 2025, to April 17, 2026, for overstating operational efficiency and product demand, while actually facing increased operating expenses and cash burn, requiring lead plaintiff motions by August 11, 2026.
- Microsoft Product Deficiencies: Microsoft Corporation (NASDAQ:MSFT) is implicated in a class action lawsuit for the period from May 1, 2025, to January 28, 2026, alleging significant issues with its Copilot product line, including poor brand positioning and user experience, leading to a decline in market share, with a lead plaintiff motion deadline of August 11, 2026.
- Black Rock Coffee Expansion Risks: Black Rock Coffee Bar, Inc. (NASDAQ:BRCB) faces a class action lawsuit for the period from September 12, 2025, to May 12, 2026, claiming that new store openings cannibalized existing services and revenue, with a lead plaintiff motion deadline of August 17, 2026.
See More
Reminder of Class Action Lawsuits for Shareholders of Multiple Companies
- BitGo Shareholder Lawsuit: BitGo Holdings, Inc. (NYSE:BTGO) faces a class action lawsuit for the period from January 22 to May 13, 2026, alleging that the company failed to disclose the impact of declining digital asset prices on its financial performance, which may undermine investor confidence and affect stock prices.
- Erasca Shareholder Class Action: Erasca, Inc. (NASDAQ:ERAS) is involved in a lawsuit for the period from January 14, 2025, to April 26, 2026, claiming that the company made improper comparisons in its ERAS-0015 preclinical data, failing to disclose potential patent and trade secret risks, which could lead to diminished investor confidence in the company's future.
- Nano-X Shareholder Lawsuit: Nano-X Imaging Ltd. (NASDAQ:NNOX) is facing a class action lawsuit for the period from March 31, 2025, to April 17, 2026, alleging that the company overstated operational efficiencies and product demand, failing to disclose misalignments between production and demand, potentially leading to increased operational costs and cash flow risks for shareholders.
- Microsoft Shareholder Class Action: Microsoft Corporation (NASDAQ:MSFT) is involved in a lawsuit for the period from May 1, 2025, to January 28, 2026, alleging that the company failed to disclose multiple issues facing its Copilot product line, including inadequate brand positioning and user experience, which may impact its market share and future revenue expectations.
See More
Erasca Faces Class Action Lawsuit Risks
- Stock Price Plunge: Erasca's shares plummeted by approximately 53.9%, resulting in an $11.59 loss per share after the revelation of improper preclinical data, indicating a significant crisis in market trust for the company.
- Class Action Initiation: Levi & Korsinsky has filed a class action lawsuit against Erasca, alleging materially false and misleading statements made between January 14, 2025, and April 26, 2026, granting investors the right to seek recovery for their losses.
- Financing Motivation Scrutiny: The lawsuit contends that the $258.8 million common stock offering completed on January 23, 2026, was aimed at maintaining an artificially inflated stock price, raising further concerns about the transparency of the company's management.
- Legal Risks Emerge: Allegations of improper comparisons in preclinical data expose Erasca to potential patent infringement and trade secret misappropriation claims, leaving investors uncertain about the company's future prospects.
See More
Erasca Faces Securities Fraud Class Action Lawsuit
- Class Action Reminder: Bernstein Liebhard LLP reminds investors of Erasca, Inc. (NASDAQ: ERAS) about the August 10, 2026 deadline for a securities fraud class action lawsuit, urging investors to submit forms promptly to participate in the litigation.
- Lawsuit Background: The lawsuit represents investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, alleging violations of the Securities Exchange Act of 1934 by the company and certain senior officers for making materially false and misleading statements regarding business operations, growth prospects, and financial stability.
- Investor Losses: Due to these alleged misrepresentations, Erasca's common stock traded at artificially inflated prices during the class period, leading to significant losses for investors when the truth was revealed, highlighting the legal risks and potential financial implications facing the company.
- Law Firm's Strength: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, demonstrating its expertise and influence in protecting investor rights.
See More
Investors Alert: Class Action Lawsuits Against BitGo and Others
- BitGo Lawsuit Reminder: A class action lawsuit against BitGo Holdings, Inc. alleges that the company failed to disclose the severe risks posed by falling digital asset prices to its financial performance, urging investors who purchased shares and suffered losses to apply for lead plaintiff status by August 7, 2026.
- ADMA Legal Issues: ADMA Biologics, Inc. faces a class action lawsuit claiming misleading statements made between August 9, 2024, and March 25, 2026, with investors needing to apply for lead plaintiff status by August 10, 2026, to protect their rights.
- Erasca Class Action: The class action lawsuit against Erasca, Inc. alleges failure to disclose material facts regarding ERAS-0015 between January 14, 2025, and April 26, 2026, with affected investors required to apply for lead plaintiff status by August 10, 2026.
- Legal Firm Overview: Holzer & Holzer, LLC, a top-rated securities litigation law firm, has been dedicated to vigorously representing shareholders since 2000, recovering hundreds of millions of dollars for victims of corporate misconduct.
See More
